(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/110872 Al 14 July 2016 (14.07.2016) P O P C T

(51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 8/97 (2006.01) A61Q 19/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IN20 16/0000 12 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 8 January 2016 (08.01 .2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 72/MUM/20 15 8 January 20 15 (08.0 1.20 15) IN GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: ZYDUS WELLNESS LIMITED [IN/IN]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, House No. 6 & 7, Sigma Commerce Zone, Sarkhej-gandh- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, inagar Highway, Ahmedabad - 380015, Gujarat (IN). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: DATTA, Hema Sharma; House No. 6 & 7, GW, KM, ML, MR, NE, SN, TD, TG). Sigma Commerce Zone, Sarkhej-gandhinagar Highway, Ahmedabad - 380015, Gujarat (IN). Declarations under Rule 4.17 : CHANDRAKANTBHAI, Mehta Arti; House No. 6 & 7, — as to applicant's entitlement to apply for and be granted a Sigma Commerce Zone, Sarkhej-gandhinagar Highway, patent (Rule 4.1 7(H)) Ahmedabad - 380015, Gujarat (IN). Published: (74) Agents: SUBRAMANIAM, Hariharan et al; Sub- ramaniam & Associates, Central Square, Suite-328, Plaza — with international search report (Art. 21(3)) III, 20 Manoharlal Khurana Marg, Bara Hindu Rao (off — before the expiration of the time limit for amending the Rani Jhansi Road), Delhi- 110006 (IN). claims and to be republished in the event of receipt of (81) Designated States (unless otherwise indicated, for every amendments (Rule 48.2(h)) kind of national protection available): AE, AG, AL, AM,

o00 o (54) Title: FOOT CARE COMPOSITIONS (57) Abstract: The present invention relates to new foot care compositions, the oily phase of which comprises extracts of at least five different wherein at least one extract is selected from the group comprising lanzan extract, cassia tora extract, pongamia glabra extract, shorea robusta extract. The invention also relates to compositions comprising such plant extracts and process for preparing these compositions. FOOT CARE COMPOSITIONS Field of invention The present invention relates to new foot care compositions, the oily phase of which comprises extracts of at least five different plants wherein at least one plant extract is selected from the group comprising buchanania lanzan extract, cassia tora extract, pongamia glabra extract, shorea robusta extract. The invention also relates to compositions comprising such plant extracts and process for preparing these compositions. Background of the invention Human skin consists of two major layers, a relatively thicker layer called dermis and a superficial layer called epidermis. The skin serves both to keep out noxious material, disease producing organisms and to keep in valuable commodities such as water. Under normal conditions of average humidity, water is lost continuously from the surface of the skin. At a very high humidity, the skin is almost water-logged, but at a very low relative humidity, the rate of loss from the skin will exceed the rate of passage from body tissue. Water content in the horny layer of the skin falls below the level required to maintain its palacity and its flexibility becomes less than that of normal skin. Changes of this nature occur at low humidity resulting in cracks of heels and sometimes in hands. Cracked heels are a common problem that may develop into painful fissures or openings if left untreated. The cracks are abnormalities in the skin resulting in pain, bleeding, sensitivity to cold and warmth. You may see dehydrated feet as a minor nuisance; however it can to further problems such as fungal infections and ulcerations. Foot care is an especially important issue for the increasing number of diabetic patients globally. Cracks in heels may be superficial, deep and very deep. The other cause of cracks in heels can be due to unknown pathological reasons and frequent exposure to detergents and dust. Skin loses its ability to stretch with age, so cracks are more common as you get older. Diabetes can interrupt the body's ability to produce oils, making the skin less supple and more susceptible to extreme dryness. Disease and disorders such as athlete's foot, psoriasis, eczema, and thyroid disease may cause cracked heels. Excess weight can create extra pressure on the feet. Prolonged standing in ill-fitting shoes can become a problem due to added pressure. Poorly structured feet can sometimes lead to abnormal gait that produces calluses to the heel. Water, especially running water, can rob the skin of its natural oils and this can leave the skin dry and rough. Deficiency of , minerals and can lead to skin breakdown as well. The cracks are socially unattractive and reduce the efficiency in the man. The healing, protection and prevention of cracks in heels and hands is generally done by emollient creams/lotions. There are several products available in market but a few but frequently reported effects include irritation, redness, itching and sensitivity to the sun. Many products need multiple applications every day, for weeks to sooth severe dryness and deep cracks. US publication number 2010/0303742 relates to skin compositions comprising hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, oil and wax; and related method for protecting, healing and/or soothing the skin. US publication number 2007/0014749 relates to a novel base material for manufacturing cream, comprising of cooling and soothing agent on the skin. The invention relates to herbal compositions suspended in a cream based on novel vehicle "Ghee" (clarified butter). In the present invention, provides a combination of extracts of natural botanicals/ formulated in a base. When applied, it reduces the rate of water loss from the surface of the cracked heels and hands to the extent that water is conserved and the horny layer hydrates. The cream is rapidly absorbed through the skin and at the same time natural herbal extracts heal the wound and prevent it from infections making the skin soft and supple. The composition helps reduce severe dryness and pain in a short period of time. Summary of the invention In one general aspect, the present invention relates to a topical composition comprising about 10% to about 30% oil extract wherein the oil extract comprises extracts of at least five different plants wherein at least one plant extract is selected from the group comprising buchanania lanzan extract, cassia tora extract, pongamia glabra extract, shorea robusta extract. In another general aspect, there is provided a topical composition, wherein at least five different plants are selected from the group comprising buchanania lanzan, cassia tora, pongamia glabra, shorea robusta. papavar somniferam, curcuma longa and helianthus annus. In another general aspect, there is provided a topical composition, wherein the oil extract comprises not more than 1% by weight of preservatives. In yet another general aspect, there is provided a topical composition, wherein the composition is in the form of creams, emulsions, dispersions, oils, ointments, balsams, lotions, gels, cream gels or liniments. In another general aspect, there is provided a topical composition, wherein the composition is in the form of cream. Embodiments of the invention may include one or more of the following features. For example the composition may further comprise one or more cosmetically or pharmaceutically acceptable ingredients comprising preservatives//chelating agents, vitamins, dyes/coloring agents, proteins/amino acids, plant extracts, humectants/conditioners/moisturizers, fragrances/perfumes, oils/emollients/lubricants, penetrants, thickeners/viscosity modifiers, surfactants/ detergents/ emulsifiers/opacifying agents, liquid vehicles/solvents and pH adjusting agents/buffers/neutralizing agents. In another general aspect, there is provided a topical composition, wherein the composition further comprises one or more cosmetically or pharmaceutically active ingredients comprising antiseptic agents, antiperspirant agents, anti-inflammatory agents and/or analgesics, anti-itching agents, calming agents, anesthetic agents, skin relaxant agents, free radical scavengers and/or agents against atmospheric pollution, reactive carbonyl species scavengers, antimicrobial agents, agents, fungistatic agents, bactericidal agents, bacteriostatic agents, agents stimulating the synthesis of dermal or epidermal macromolecules and/or capable of inhibiting or preventing their degradation, collagen synthesis-stimulating agents, elastin synthesis-stimulation agents, agents stimulating the synthesis of lipids and components of the stratum corneum, ceramides, fatty acids, agents that inhibit collagen degradation, matrix metalloproteinase inhibitory agents, agents that inhibit elastin degradation, comedolytic agents, , stabilizers, agents for the treatment and/or care of sensitive skin, binding agents, agents regulating sebum production, agents stimulating healing, coadjuvant healing agents, agents stimulating reepithelialization and coadjuvant reepithelialization agents. In another general aspect, there is provided a topical composition wherein the oil extract is prepared by a process comprising the steps: - weighing, drying and powdering the plants, extracting the powder with a solvent by soaking for about 2 hours at a temperature between 70°-80°C followed by extracting at a temperature between 98°-105°C at reflux for about 4 hours, filtering the extract and adding one or more preservatives, adding one or more cosmetically or pharmaceutically acceptable ingredients, evaporating the water at 98-100°C to obtain hot oil extract, adding one or more antioxidants to the extract, and cooling the oil extract obtained. In another general aspect, there is provided a topical composition, wherein the composition is prepared by a process comprising the steps: - heating water to about 80- 100°C, adding one or more cosmetically or pharmaceutically acceptable ingredients to form the aqueous phase and mixing while maintaining the temperature at 85°C, mixing oil extract with one or more cosmetically or pharmaceutically acceptable ingredients, adding oil phase into aqueous phase at about 80°C and mixing, cooling the mixture to below 45°C and further adding one or more ingredients including perfumes to the mixture to obtain final composition. In another aspect, the present invention provides a combination of extracts of natural botanicals/herbs formulated in a base. When applied, it reduces the rate of water loss from the surface of the cracked heels and hands to the extent that water is conserved and the horny layer hydrates. The cream is rapidly absorbed through the skin and at the same time natural herbal extracts heal the wound and prevent it from infections making the skin soft and supple. The details of one or more embodiments of then invention are set forth in the description below. Other features of the invention will be apparent from the description. Detailed description of the invention The present invention relates to a foot care formulation of herbal cream. Since the components in the formulation are from herbal sources it is very safe and ecofriendly and does not produce any adverse effect on the skin. It comprises wound healing herbal extract comprising buchanania lanzan, cassia tora, pongamia glabra, shorea robusta. papavar somniferam, curcuma longa and helianthus annus, and fragrant oil. The wound healing herbal extract acts as a humectant, prevents infection and heals the cracks quickly and effectively. The cream spreads evenly and smoothly when applied on the affected parts. The composition occludes and prevents water loss from effected parts, which quickens healing and restores the natural softness and suppleness and also serves as an antiseptic. The present invention also provides for masking of malodors. Although the compositions of the invention provides for masking of the malodor by incorporation of fragrant oils, it advantageously helps preventing the growth of small microorganisms responsible for the odor by incorporation of plant extracts having antibacterial properties and may further comprise other antibacterial agents. For the purposes of the application the term "plant extract" refers to the extracts obtained by separation of medicinally active portions of plant from the inert components by using selective solvents in standard extraction procedures. These include classes of preparations known as decoctions, infusions, fluid extracts, tinctures, pilular (semisolid) extracts and powdered extracts. Curcuma longa is commonly used in cooking it adds a distinctive flavor and color to foods. It is also prized for its medicinal properties. is used to treat and help prevent a wide range of diseases including rheumatoid arthritis, Alzheimer's disease and . For centuries it has been applied as a paste on skin eruptions and to heal damaged and dry skin. It is also well known for its anti- bacterial properties. It has the tendency to stain because of its deep yellow colour. Buchanania lanzan has been used in ointments to cure itches, blemishes, rashes and spots. It belongs to the family. The incorporation of the fat/extract of Shorea robusta provides, principally, softness and unctuousness during application of the compositions to the skin and provides a non- shiny, soft and protective film. The extract comes from the stones of the fruits of the tree of the same name which grows essentially in India. The Pongamia pinnata, commonly known as 'Karanj', has been recognized in different system of traditional medicines for the treatment of different diseases and ailments of human beings. It contains several phytoconstituents belonging to category flavonoids and fixed oils. The fruits and sprouts of P. pinnata were used in folk remedies for abdominal tumours in India, the seeds for keloid tumours in Sri Lanka and a powder derived from the plant for tumours in Vietnam. In Sanskritic India, seeds were used for skin aliments. Today, the oil is used as a liniment for rheumatism. Leaves are active against Micrococcus; their juice is used for cold, cough, diarrhoea, dyspepsia, flatulence, gonorrhoea and leprosy. Roots are used for cleaning gums, teeth and ulcers. Bark is used internally for bleeding piles. The present invention incorporates the oils from the plant which serves as an antiseptic. Cassia tora is a dicot legume known as sickle senna or sickle pod. The plant and seeds are edible. Since Cassia tora has an external germicide and antiparasitic character, it has been used for treating skin diseases such as leprosy, ringworm, itching and psoriasis and also for snakebites. Other medicinal provisions from plant parts include balm for arthritis using leaves of Cassia tora, Papaver somniferum. The oil and seed of the white poppy contains at most negligible amounts of opium and are therefore toxicologically irrelevant. The oils have advantageously been found to restore skin's natural barrier function and incorporation of the oil in the present composition has been found to enhance the organoleptic properties of the composition while providing rapid absorption. The composition of the present invention is a novel mixture of plant extracts and one or more cosmetically or pharmaceutically acceptable ingredients characterized in that the combination is effective in reducing severity of foot cracks and other symptoms such as dryness and pain from week 1 of application. The compositions may include one or more preservatives, antioxidants, chelating agents to extend the shelf-life and/or prevent the degradation of the components of the inventive composition. Antioxidants used in topical compositions include reducing agents and/or free radical scavengers. Exemplary preservative, antioxidants, and chelating agents useful in the inventive compositions include methylisothiazolinone, C (ascorbic acid), , , , carotenes (e.g., beta-carotene), alpha- (), ubiquinol (coenzyme Q), , tetraacetic acid (EDTA) and thereof, citric acid and salts thereof, EGTA, aminotrimethylene phosphonic acid, , flavonoids, lycophene, propyl gallate, tertiary butylhydroquinone, , , benzoates, nitrites, nitrates, sulfites, propionate, bisulfite, hydrogen sulfite, benzyl alcohol, methylparaben, propylparaben, imidazolidinylurea, dioxide, and combinations thereof. Exemplary antioxidants include acer palmatum leaf extract, acetamidocaproic acid, acetyl benzoyloxy , acetyl , agrimonia eupatoria root extract, aminoethanesulfinic acid, aminopropyl ascorbyl phosphate, aminopropyl tocopheryl phosphate, anserine, arbutin, alphaarbutin, ascorbyl dipalmitate, ascorbyl glucoside, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, ascorbyl tetraisopalmitate, ascorbyl tocopheryl maleate, asiaticoside, avena sativa (oat) kernel extract, bacillus/ rice bran extract/soybean extract ferment filtrate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), bis-demethoxycurcumin, citrus medica vulgaris fruit extract, coptis chinensis root extract, crotonaldehyde, , cyamopsis tetragonoloba (guar) symbiosome extract, cysteine, cysteine hci, decyl mercaptomethylimidazole, demethoxycurcumin, diamylhydroquinone, di-tbutylhydroquinone, dicetyl thiodipropionate, dicyclopentadiene/ t-butylcresol copolymer, digalloyl trioleate, dilauryl thiodipropionate, dimethoxy di-p-cresol, dimethylmethoxy chromanol, dimyristyl thiodipropionate, dioleyl tocopheryl methylsilanol, diosmine, disodium ascorbyl sulfate, disodium rutinyl disulfate, distearyl thiodipropionate, glycyrrhiza glabra (licorice) root extract, grifola frondosa fruit body extract, alternifolia (tea tree) leaf oil, melatonin, melia azadirachta conditioned media/culture, methoxy PEG-7 ascorbic acid, methoxy-peg-7 rutinyl succinate, methoxytrimethylphenyl dihydroxyphenyl, propanol, methyl~ne di-t-butylcresol, palmitoyl camellia sinensis extract, palmitoyl grape seed extract, PEG/PPG-2/5 tocopheryl ether, PEG/PPG-5/10 tocopheryl ether, PEG/PPG-5/20 tocopheryl ether, PEG/PPG-5/30 tocopheryl ether, PEG/PPG-30/10 tocopheryl ether, PEG/ PPG-50/20 tocopheryl ether, PEG/PPG-70/30 tocopheryl ether, PEG/PPG- 1 00/70 tocopheryl ether, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, ocymoides seed extract, phenylthioglycolic acid, phloroglucinol, pike a robusta extract, pinus pinaster bark extract, pinus radiata bark extract, piper nigrum () seed, pisum sativum symbiosome extract, platycodon grandiflorum root extract, polygonum cuspidatum root extract, potassium ascorbyl tocopheryl phosphate, potassium sulfite, PPG-2 tocophereth-5, PPG-5 tocophereth-2, PPG- 0 tocophereth- 30, PPG-20 tocophereth-50, PPG-30 tocophereth-70, PPG- 70 tocophereth-100, PPG-5 tocopheryl ether, prop_yl g_allate, prunus cerasus (bitter cherry) extract, pyndoxme serinate, , quercetin caprylate, resveratrol, rhodochrosite extract, rosmarinic acid, rosmarinus Officinalis () flower extract, sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium phosphono-pyridoxylidenerhodanine, sodium sulfite, sodium thioglycolate, sodium tocopheryl phosphate, sorbity.l furfural, TBHQ, tetrabutyl ethylidinebisphenol, tetrad 1butyl pentaerithrityl hydroxyhydrocinnamate, tetrahexyldecylascorbate, tetrahydrobisdemethoxydiferuloylmethane, tetrahydrodemethoxydiferuloylmethane, tetrahydrodiferuloylmethane, tetramethylchromanol glucosides, thioctic acid, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, thiotaurine, tococysteamide, tocophereth- 5, tocophereth-10, tocophereth- 12, tocophereth- 18, tocophereth-50, tocopherol, tocophersolan, tocopheryl acetate, tocopheryt linoleate, tocopheryl linoleate/oleate, tocopheryl nicotinate, tocopheryl succinate, tocoquinone, toluene, o-tolyl biguanide, totaro!, tremella fuciformis extract, trifolium pratense (clover) symbiosome extract, trigonella foenum symbiosome extract, tripropylene glycol, tris(nonylphenyl) phosphite, trisodium fructose diphosphate. Exemplary chelating agents useful in accordance with the present invention include acrylic acid/acrylamidomethyl propane . sul~onic acid copolymer, beta-alanine diacetic acid, ammotnmethylene phosphonic acid, calcium disodium EDTA, citric acid, cyclodextrin, cyclohexanediamine tetraacetic acid, diammonium citrate, diammonium EDTA, diethylenetriamine pentamethylene phosphonic acid, dipotassium EDTA, disodium azacycloheptane diphosphonate, disodium EDTA, disodium pyrophosphate, EDTA, etidronic acid, galactaric acid, galacturonic acid, alpha-glucan, gluconic acid, glucuronic acid, HEDTA, humic acids, hydroxypropyl cyclodextrin, lauroyl ethylenediamine triacetic acid, methyl cyclodextrin, methyl dihydroxybenzoate, oxyquinoline, oxyquinoline sulfate, pentapotassium triphosphate, pentasodium aminotrimethylene phosphonate, pentasodium ethylenediamine tetramethylene phosphonate, pentasodium pentetate, pentasodium triphosphate, penteticacid, phosphonobutanetricarboxylic acid, phytic acid, potassium citrate, potassium EDTMP potassium gluconate, potassium polyphosphate, potassium trisphosphonomethylamine oxide, ribonic acid, sodium chitosan methylene phosphonate, sodium citrate, sodium diethylenetriamine pentamethylene phosphonate, sodium dihydroxyethyl glycinate, sodium EDTMP, sodium gluceptate, sodium gluconate, sodium glycereth-1 polyphosphate, sodium hexametaphosphate, sodium lauroyl ethylenediamine triacetate, sodium metaphosphate, sodium metasilicate, sodium phytate, sodium polydimethylglycinophenolsulfonate, sodium polyphosphate, sodium trimetaphosphate, TEA-cocamide diacetate, TEA-EDTA, TEA-polyphosphate, tetrahydroxyethyl ethylenediamine, tetrahydroxypropyl ethylenediamine, tetrahydroxypropyl ethylenediamine dioleate, tetrapotassium etidronate, tetrapotassium pyrophosphate, tetrasodium dicarboxymethyl aspartate, tetrasodium EDTA, tetrasodium etidronate, tetrasodium glutamate diacetate, tetrasodium imminodisuccinate, tetrasodium pyrophosphate, tripotassium EDTA, trisodium dicarboxymethyl alaninate, trisodium EDTA, trisodium ethylenediamine disuccinate, trisodium fructose diphosphate, trisodium HEDTA, trisodium NTA, and trisodium phosphate. In certain embodiments, the preservative is ascorbic acid. In certain embodiments, the preservative is butylated hydroxytoluene (BHT). In certain embodiments, the preservative is tocopherol acetate. In certain embodiments, the preservative is a combination of butylated hydroxytoluene (BHT), ascorbic acid or a derivative thereof (e.g., palmitate), and tocopherol or a derivative thereof. In certain embodiments, the preservative is Germazide PMP. The composition of the present invention may include 0% to about 4% by weight of the preservative, , or chelating agent. In certain embodiments, the composition includes about 0.01% to about 5% by weight of the preservative, antioxidant, or chelating agent. In certain embodiments, the composition includes about 0.05% to about 3% by weight of the preservative, antioxidant, or chelating agent. In certain embodiments, the composition includes about 0.01% to about 2% by weight of the preservative, antioxidant, or chelating agent. In certain embodiments, the composition includes about 0.1% to about 1% by weight of the preservative, antioxidant, or chelating agent. The compositions of the present invention may include one or more of a vitamin to nourish or replenish the treated skin. Exemplary vitamins include , vitamin B

(thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B (adenine), vitamin B

(), vitamin B (pyridoxine), vitamin B (), vitamin B9 (folic acid), vitamin BJ2 (), vitamin C (ascorbic acid), (ergocalciferol), vitamin E (tocopherol), , and combinations thereof. Salts, esters, and other forms of a vitamin are also acceptable for use in the invention.. The inventive composition may include 0% to about 10% by weight of the vitamin. In certain embodiments, the composition includes about 0.0001% to about 5% by weight of the vitamin. In certain embodiments, the composition includes about 0.001% to about 5% by weight of the vitamin. In certain embodiments, the composition includes about 0.0005% to about 3% by weight of the vitamin. In certain embodiments, the composition includes about 0.001% to about 2% by weight of the vitamin. The compositions of the present invention may include one or more dye or other coloring agent. Any dye or coloring agent approved for use on humans by the U.S. Food and Drug Administration may be used in the inventive compositions. In certain embodiments, the dye or coloring agent is a FD&C or D&C dye, lake, or pigment. Such materials are well known in the art. Exemplary dyes and coloring agents include but are not limited to 1,7- dihydroxyaphthalene; 1,3-diaminobenzene; -methyl -2,5-diaminobenzene; 1,4- diaminobenzene; 1,3-Dihydroxybenzene; 1,3-Benzenediol, 4-chloro-; l-Hydroxy-2- aminobenzene; 3-amino-phenol; l-Hydroxy-4-aminobenzene; 1-Hydroxynaphthalene; 1,5- Dihydroxynaphthalene; 2,7-Dihydroxynaphthalene; 1,4-Dihydroxybenzene; l-Hydroxy-4- methylaminobenzene; 6-Hydroxybenzomorpholine; l-Methyl-2-hydroxy-4-aminobenzene; 1- Methyl-2-hydroxy-4-(2'-hydroxyethyl)aminobenzene; 1-Phenyl-3 -methylpyrazol-5-on; 1- (2'Hydroxyethyloxy)-2,4-diaminobenzene hydrochloride; l,3-Dihydroxy-2-methylbenzene; l-Amino-4-bis-(2'-hydroxyethyl)aminobenzene sulfate; l-Hydroxy-3-methyl-4- aminobenzene; l-Hydroxy-2-amino-5-methylbenzene; l-(2'-Hydroxyethyl)2,5- diaminobenzene sulfate; l-Methoxy-2-amino-4-(2'-hydroxyethylamino)benzene; 3,5- Pyridinediamine, 2,6-dimethoxy-, dihydrochloride; 4-Amino-2-aminomethylphenol HC1; 6- Hydroxyindole; 2,3-Indolinedione; 2-Amino-3-hydroxypyridine; 2,4-Dinitro-3'-sulfo-4'- phenylaminodiphenylamine; Ethanol, 2-[(4-amino-3-nitrophenyl)amino]-; Ethanol, 2,2'-[[4- [(2-hydroxethyl)amino]-3-nitrophenyl]imino]bis-; N,0-Di(hydroxyethyl)-2-amino-5- nitrophenol; l-(2'-Hydroxyethyl)amino-2-nitrobenzene; 2-Nitro-4'-hydroxydiphenylamine; 2- Nitro-4-aminodiphenylamine and 2-Chloro-5-nitro-n-hydroxyethyl-p-phenylenediamine. The compositions of the present invention may include one or more of a protein, peptide, or amino acid. Such ingredients may be added to the inventive composition to nourish the skin, impart a desired characteristic to skin, or impart a desired characteristic to the composition (e.g., thickening the composition). Exemplary proteins that may be added to inventive compositions include elastin, fibrillin, fibronectin, laminin, keratin, proteoglycans, wheat protein, gelatin, collagen, silk, soy protein, wheat protein, rice protein, corn protein, jojoba protein, milk protein, whey protein, casein, albumin, egg protein, and fragments thereof. As would be appreciated by one of ordinary skill in the art, derivatives, mutants, fusion proteins, fragments, or combinations of any of these proteins may also be included in the inventive cosmetic composition. In certain embodiments, any of the twenty natural amino acids may be included in the inventive cosmetic composition. In certain embodiments, the proteins, peptides, or amino acids are included in the composition in a range from about 0.0001% to about 10% by weight. In certain embodiments, the proteins, peptides, or amino acids are included in the composition in a range from about 0.01% to about 5% by weight. Other plant extracts useful in implementing the teachings of the present invention include but are not limited to acacia arabica gum, acacia concuine pods, acacia decurrens willd. var. dealbata absolute french, acacia decurrens willd. var. dealbata bark australia, acacia false bark (robinia pseudacacia), acacia farnesiana 1. willd. absolute, acacia glaucophylla staud. gum, acacia gum (acacia Senegal 1. willd), acacia niopo seed, achillea coronopifolia oil, achillea millefolium 1. oil, aconite england (aconitum napellus linn.), acorus calamus 1. oil, adder's tongue america (erythronium americanum ker-gawl), adrue jamaica (cyperus articulatus linn.), rose. k. schum. oil, aframomum melegueta rose, oil, agal agal gum, agar gum, agar wood oil (aquilaria agallocha), agastache foeniculum oil, agathis australis leaf oil, agathis australis oil, agrimony (eupatorium cannabinum linn.), ajowan seed oil (trachyspermum ammi), alder bark common (alnus glutinosa gaertn.), alder bark tag (alnus serrulata willd.), algae absolute brown, algae absolute brown, algae absolute green, algae absolute green, alkanet root (alkanna tinctoria tausch.), allium cepa 1. oil, allium cepa 1. oleoresin, allium sativum 1. oil china, allium sativum 1. oleoresin, oil (pimenta officinalis lindl.), allspice oleoresin (pimenta officinalis lindl.), oil bitter (amygdalus communis linn. var. amara), bitter, almonds sweet, alnus rubra bark (alnus serrulata willd.), aloe barbadensis leaves, aloe leaves, aloe vera linn, leaves, aloe wood gum, 1. oleoresin, alpinia officinarum 1. root oil, alstonia constricta f. muell. bark, alstonia scholaris, amber oil, ambrette seed (hibiscus abelmoschus), ambrette seed absolute (hibiscus abelmoschus), ambrette seed oil (hibiscus abelmoschus), ambrette seed resinoid (hibiscus abelmoschus), american greek valerian root, american mountain ash (pyrus americana d. c), american pulsatilla, ammomum melegueta oil, ammoniacum gum (dorema ammoniacum d. don.), amygdalus communis linn. var. amara oil, amyris wood oil (amyris balsamifera), andropogon schoenanthus oil india, anethum graveolens, anethum sows d. c. seed oil and extract. The compositions of the present invention may include one or more of a humectant/conditioner/moisturizer. A humectant is a hydrogroscopic substance. It is typically a chemical compound containing hydrophilic groups such as hydroxyl groups, amines, carboxylates, , esters, etc. Humectants are typically found in compositions to reduce static and/or to provide a moisturizing quality to the composition. The humectants attract and hold moisture on the skin. Examples of humectants useful in the inventive compositions include but are not limited to acetyl , ascorbic acid, diglycerin, erythritol, fructose, glucose, inositol, lactitol, lactose mannose, methylglucamine, methylpropanediol, phytantriol, raffinose, riboflavin, maltose, glycerin, glycerol, hyaluronic acid, atelocollagen, propylene glycol, glyceryl triacetate, polyols, sorbitol, sorbityl acetate, sorbityl furfural, sorbityl silanediol, xylose, tromethamine, zinc glucoheptonate, xylitol, maltitol, polydextrose, quillaia, lactic acid, sodium lactate, triacetin, urea, acetyl arginine, acetyl hydroxyproline, adansonia digitata fruit extract, adenophora stricta root extract, agave atrovirens extract, alanyl , alcaligenes polysaccharides, algae extract, aloe barbadensis leaf extract, aloe barbadensis leaf polysaccharides, amidinoproline, bacillus/rice bran extract/soybean extract ferment filtrate, betaine, bittern, black strap powder, 2,3-butanediol, caprylyl glycol/glycerin/polyacrylic acid copolymer, hci, chitosan lauroyl glycinate, cholesterol/hdi/pullulan copolymer, coix lacryma-jobi (job's tears) shell extract, coleus forskohlii root extract, cryptomeria japonica leaf extract, cucumis melo (melon) fruit water, diglycereth-7 malate, diglycerin, diglycol guanidine succinate, dunaliella bardawil extract, earthworm conditioned soil, earthworm conditioned soil extract, erythritol, ethylhexyl hydroxystearoyl hydroxystearate, fructose, glucose, glucosyl hesperidin, glucuronolactone, glycereth-7 glycolate, glycerin, glyceryl citrate crosspolymer, glyceryl dimaltodextrin, glycol, glycosyl trehalose, hesperetin laurate, 1,2,6-hexanetriol, honey, hydrogenated honey, hydrogenated isocetyl olivate, hydrogenated starch hydrolysate, hydrolyzed wheat protein/PEG-20 acetate copolymer, hydroxypropyltrimonium hyaluronate, impatiens balsamina extract, inositol, isostearyl acetyl glutaminate, jojoba amino acids, lactic acid, lactitol, lactobaccillus/phoenix dactylifera (date) fruit ferment extract, lauramidobutyl guanidine acetate, lauramidobutyl guanidine hci, laur/myrisupalmitamidobutyl guanidine acetate, lauryl malamide, lonicera caerulea fruit juice, lonicera caerulea fruit water, lysophosphatidylethanolamine, malpighia emarginata (acerola) seed extract, maltitol, maltose, mannitol, mannose, methoxy PEG-7, methoxy PEG-10, methoxy PEG-16, methoxy PEG-25, methoxy PEG-40, methoxy PEG- 100, momordica charantia fruit extract, myrciana dubia seed extract, myristamidobutyl guanidine acetate, myrist/palmitamidobutyl guanidine acetate, palmitamidobutyl guanidine acetate, PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG- 10, PEG-12, PEG-14, PEG-16, PEG-18, PEG-20, PEG-32, PEG-33, PEG-40, PEG-45, PEG- 55, PEG-60, PEG-75, PEG-80, PEG-90, PEG-100, PEG-135, PEG-150, PEG-180, PEG-200, PEG-220, PEG-240, PEG-800, PEG- 5 butanediol, PEG-3 methyl ether, PEG-4 methyl ether, PEG-8 methyl ether dimethicone, PEG-5 pentaerythrityl ether, PEG/PPG-28/21 acetate dimethicone, PEG/PPG-23/23 butyl ether dimethicone, PEG/PPG-24/18 butyl ether dimethicone, persea thunbergii extract, polydimethylsiloxy PPG- 3 butyl ether silsesquioxane, polyglyceryl sorbitol, polyquaternium-64, polyquaternium-65, potassium dextrin octenylsuccinate, potassium PCA, PPG- 12 butyl ether dimethicone, PPG-6-sorbeth- 245, PPG-6-sorbeth-500, PPG-2 tocophereth-5, propylene glycol, prunus mume fruit extract, pseudoalteromonas ferment extract, rosa canina seed extract, saccharomyces/prunus extract ferment filtrate, schizophyllan, sea water, sodium acetylated hyaluronate, sodium dextrin octenylsuccinate, sodium glucuronate, sodium PCA, sorbeth-6, sorbeth-20, sorbeth-30, sorbeth-40, sorbitol, sorbityl silanediol, stearyl acetyl glutaminate, stearyl palmitate, sucrose, TEA-dextrin octenylsuccinate, trehalose, triglycereth-7 citrate, trimethylamine oxide, trioxaundecanedioic acid, tripropylene glycol, urea, urea-d-glucuronic acid, xylitol, xyloglucan, and xylose. The humectant is used in the composition in an amount ranging from about 0.01% to about 30% by weight. In certain embodiments, the humectant is used in the cosmetic composition in an amount ranging from about 0.1% to about 20% by weight. In certain embodiments, the humectant is used in the cosmetic composition in an amount ranging from about 1% to about 25% by weight. In certain embodiments, the humectant is used in the cosmetic composition in an amount ranging from about 1% to about 10% by weight. The compositions of the present invention may include one or more of a fragrance or perfume. Fragrance ingredient, as defined by the International Fragrance Association, is "any basic substance used in the manufacture of fragrance materials for its odorous, odor- enhancing, or blending properties. Fragrance ingredients may be obtained by chemical synthesis from synthetic, fossil, or natural raw materials, or by physical operations from natural sources. The function comprises aroma chemicals, essential oils, natural extracts, distillates and isolates, oleoresins, etc." In certain embodiments, a fragrance is any natural or synthetic substance or substances used solely to impart an odor to a cosmetic product. In certain embodiments, the perfume or fragrance is commercially available. In certain embodiments, the perfume or fragrance may be blended from raw ingredients used in the cosmetics industry. Exemplary fragrance ingredients include abies alba leaf oil, abies balsamea (balsam canada) resin, abies pectinata oil, abies sibirica oil, acacia catechu gum, acacia Senegal gum, acetaldehyde, acetanilid, acetyl hexamethyl indan, acetyl hexamethyl tetralin, acetyl tributyl citrate, acetyl triethyl citrate, achillea millefolium extract, achillea millefolium flower water, achillea millefolium oil, achyrocline satureiodes flower oil, actinidia chinensis (kiwi) fruit water, adipic acid, agar, agropyron repens root extract, alanine, albizia julibrissin bark extract, alcohol, alcohol dena , algae extract, algin, allyl caproate, aloe barbadensis leaf, aloe barbadensis leaf water, amidinoproline, aminomethyl propanediol, ammonia, ammonium chloride, ammonium glycyrrhizate, amyl acetate, amyl benzoate, amyl cinnamal, amylcinnamyl alcohol, amyl salicylate, amyris balsamifera bark oil, anethole, angelica archangelica root extract, angelica archangelica root oil, aniba rosaeodora (rosewood) wood extract, fruit extract, citrus medica limonum (lemon) fruit water, citrus medica limonum (lemon) peel oil, citrus medica vulgaris peel oil, citrus nobilis (mandarin orange) fruit extract, citrus nobilis (mandarin orange) peel extract, citrus nobilis (mandarin orange) peel oil, citrus reticulata leaf oil, citrus tangerina (tangerine) peel oil, rosmarinus officinalis (rosemary) water, rubus fruticosus (blackberry) fruit extract, rubus fruticosus (blackberry) leaf extract, rubus idaeus (raspberry) fruit water, rubus idaeus (raspberry) leaf wax, (rue) oil, saccharin, salicylic acid, salvia lavandulaefolia oil, (sage) leaf water, salvia officinalis (sage) oil, salvia sclarea (clary) oil, sambucus nigra oil, sambucus nigra wax, santalum album (sandalwood) oil, oil and the like. The compositions of the present invention may include one or more of oil, emollient or lubricant. These terms are used interchangeably herein. Oils are used in compositions for moisturization and nourishment. In certain embodiments, oil is any fatty substance which is liquid at room temperature (25°C). Exemplary oils, emollients, lubricants include butters example kokum butter; silicone oils; phenylsilicones; silicone resins; silicone gums; mineral oils such as paraffin oil or vaseline oil; oils of animal origin such as perhydrosqualene, squalene, lanolin; oils of plant origin such as liquid triglycerides, e.g., sunflower oil, corn oil, soybean oil, rice oil, jojoba oil, babusscu oil, pumpkin oil, grapeseed oil, oil, walnut oil, apricot oil, macadamia oil, avocado oil, sweet almond oil, castor oil, triglycerides of caprylic/capric acids, olive oil, peanut oil, rapeseed oil, and coconut oil; synthetic oils such as purcellin oil, isoparaffins, linear and/or branched fatty alcohols and fatty acid esters, esters such as dioctyl adipate, diisopropyl dimer dilinoleate; propylene glycols/dicaprylate or waxes such as beeswax, paraffin wax or microwaxes, alone or in combination with hydrophilic waxes, such as cetylstearyl alcohol, for example; fluorinated and perfluorinated oils; fluorinated silicone oils; mixtures of the aforementioned compounds. Exemplary plant derived oils include almond oil, apricot kernel oil, arnica oil, avocado oil, babusscu oil, black seed oil, seed oil, castor oil, coconut oil, colza oil, corn oil, cotton seed oil, cowslip oil, evening primrose seed oil, grapeseed oil, hazelnut oil, hemp seed oil, jojoba oil, kukui nut oil, lady's-smock oil, , macadamia nut oil, menhaden oil, neem seed oil, olive oil, palm oil, palm seed oil, peanut oil, pine oil, seed oil, pumpkin seed oil, rape oil, rapeseed oil, rice oil, rice palm oil, rosehip seed oil, safflower oil, seabuckthorn oil, sesame oil, sesame seed oil, shea nut oil, soya oil, soybean oil, sunflower oil, tamanu oil, vitamin E oil, wheat germ oil, and walnut oil. Exemplary animal-derived oi s include squalene, perhydrosqualene, and lanolin. In certain embodiments, the oil is a glyceryl ester which is primarily a fatty acid mono-, di-, or triglyceride modified by reaction with other alcohols, for example, acetylated castor oil, glyceryl stearate, glyceryl dioleate, glyceryl distearate, glyceryl trioctanoate, glyceryl distearate, glyceryl linoleate, glyceryl myristate, glyceryl isostearate, PEG castor oils, PEG glyceryl oleates, PEG glyceryl stearates, PEG glyceryl tallowates, etc. In certain embodiments, the oil is a sorbitan derivative. In certain embodiments, the emollient is isopropyl myristate or cetosteryl alcohol. In certain embodiments, the oil is used in the composition in an amount ranging from about 1% to about 20% by weight. In certain embodiments, the oil is used in the cosmetic composition in an amount ranging from about 1% to about 10% by weight. The compositions of the present invention may include one or more of a thickening agent or a viscosity modifier. The thickening agent may be a natural or synthetic thickening agent. In certain embodiments, the thickening agent is polymeric. In certain embodiments, the thickening agent is a polysaccharide. In certain embodiments, the thickening agent is a protein. In certain embodiments, the thickening agent is a low wax. Examples of low melting point waxes include emulsifying wax, and fatty alcohols having the formula R--OH, wherein R is a straight or branched chain, unsaturated or unsaturated alkyl moiety having from about 4 to 35, more preferably about 6 to 22, carbon atoms. Examples of fatty alcohols include stearyl alcohol, cetearyl alcohol, behenyl alcohol, and the like. In certain embodiments, the thickening agent is a synthetic polymeric thickener. Examples of synthetic polymeric thickeners include polymers of acrylic acid, methacrylic acid and their simple esters, which may be co-polymerized with one or more organic groups such as ethoxylated or , propoxylated polymeric moieties. The compositions of the present invention may include one or more of surfactants, detergents or emulsifiers. The terms can be used inter- changeably. Such agents may work to make the final composition homogenous or help to solubilize certain ingredients of the composition. Surfactants suitable for the purpose of the present invention include anionic, cationic, non-ionic, zwitterionic or amphoteric surfactants. The surfactant used in the inventive composition may be chosen based on its HLB (Hydrophilic-Lipophilic Balance) value. In certain embodiments, the surfactant has an average HLB of less than or equal to about 10. In certain embodiments, the surfactant has an average HLB of greater than or equal to about 10. In certain embodiments, the surfactant has an average HLB of ranging from about 10 to about 15. In certain embodiments, the surfactant has an average HLB of ranging from about 10 to about 12. In certain embodiments, the surfactant has an average HLB of ranging from about 12 to about 18. Exemplary surfactants useful in the present invention include but are not limited to polysorbate 80, sodium dioctyl sulfo succinate, sodium dodecyl sulfate, cocoamidopropyl betaine, and sodium laureth sulfate, alkyl and alkyl ether sulfates, succinamates, sulfosuccinamates, olefin sulfonates, hydroxy-alkanesulfonates, beta-alkyloxy alkane sulfonates, dioctyl esters of sodium sulfosuccinic acid, alkyl ethoxylated sulfates, alkyl sulfates, aliphatic secondary and tertiary amines, alkyl amphoglycinates; alkyl amphopropionates; alkyl ethoxylated sulfates; alkyl sulfates; aliphatic quaternary ammonium compounds; silicone copolyols (e.g., diinethicone copolyols), stearamide diethanolamide (DEA), cocamide monoethanolamide (MEA), glyceryl monoleate, sucrose stearate, cetheth-2, poloxamer 181, hydrogenated tallow DEA, polyoxyethylene 4 sorbitol beeswax derivative (ATLAS 6-1702), polyoxyethylene 2 cetyl ether (BRIJ 52), polyoxyethylene 2 stearyl ether (BRIJ 72), polyoxyethylene 2 oleyl ether (BRIJ 92), polyoxyethylene 2 oleyl ether (BRIJ 93), sorbitan monopalmitate (SPAN 40), sorbitan monostearate (SPAN 60), sorbitan tristearate (SPAN 65), sorbitan monoleate, NF (SPAN 80) sorbitan trioleate (SPAN 85), fluorinated alkyl quaternary ammonium iodide; mixed mono- and bis-perfluoroalkyl phosphates, ammonium salts; mixed mono- and bis- fluoroalkyl phosphate, ammonium salts; perfluoroalkyl sulfonic acid, ammonium salts; mixed telomer phosphate diethanolamine salts; amine perfluoroalkyl sulfonates; ammonium perfluoroalkyl sulfonates; potassium perfluoroalkyl sulfonates; potassium fluorinated alkyl carboxylates; ammonium perfluoroalkyl sulfonates; and ammonium perfluoroalkyl carboxylates; cetosteryl alcohol, glyceryl monostearate and stearic acid. The compositions of the present invention may include one or more of vehicles/solvents. Exemplary solvents useful in the inventive compositions include but are not limited to water, acetone, alcohol, alcohol denatured, amyl acetate, benzyl alcohol, benzyl benzoate, benzyl glycol, benzyl laurate, benzyl laurate/myristate/palmitate, 1,4-butanediol, 2,3-butanediol, buteth-3, butoxydiglycol, butoxyethanol, butoxyethyl acetate, butyl acetate, n-butyl alcohol, t-butyl alcohol, butylene glycol, butylene glycol propionate, butyl ethylpropanediyl ethylhexanoate, butyl lactate, butyloctanol, butyloctyl benzoate, butyloctyl salicylate, butylphthalimide, butyrolactone, C8-12 acid triglyceride and CI2-18 acid triglyceride. The compositions of the present invention may include one or more of pH adjusting agents/buffers/neutralizing agents. Exemplary pH buffering agents useful in the present invention include but are not limited to aluminum glycinate, aluminum lactate, ammonium acetate, ammonium carbonate, ammonium hexafluorophosphate, ammonium lactate, ammonium phosphate, boric acid, calcium carbonate, calcium phosphate, cyclohexylamine, diammonium citrate, diammonium phosphate, diethanolamine bisulfate, diethylamine, diethyl ethanolamine, disodium fumarate, disodium phosphate, disodium pyrophosphate, ectoin, ethanolamine HCI, , hydroxyethylpiperazine ethane sulfonic acid, lauryl p- cresol ketoxime, lithium fluoride, acetate, MEA-Boate, MIPArate, PEG- 114ylether. The concentration of the pH adjusting agent, buffer, or neutralizing agent in the final composition is in the range from about 0.01% to about 5% by weight. In certain embodiments, the concentration of the agent is about 0.1% to about 3% by weight. In certain embodiments, the concentration of the agent is about 0.1% to about 1% by weight. The compositions of the present invention may include one or more of absorbents. Absorbents are typically ingredients with a large surface area which can attract other materials such as lipids. Exemplary absorbents useful in accordance with the present invention include but are not limited to acrylates/bis-hydroxypropyl dimethicone, crosspolymer, acrylates crosspolymer, activated clay, alumina magnesium metasilicate, aluminum silicate, aluminum starch octenylsuccinate, ammonium silver zinc aluminum silicate, amylodextrin, attapulgite, avena sativa (oat) bran, avena sativa (oat) kernel flour, avena sativa (oat) kernel meal, avena sativa (oat) starch, bentonite, butyl acrylate crosspolymer, calamine and calcium silicate. The compositions of the present invention may further comprise one or more cosmetically or pharmaceutically active ingredients comprising antiseptic agents(e.g., Zinc oxide), antiperspirant agents, anti-inflammatory agents and/or analgesics, anti-itching agents, calming agents, anesthetic agents, skin relaxant agents, free radical scavengers and/or agents against atmospheric pollution, reactive carbonyl species scavengers, antimicrobial agents, antifungal agents, fungistatic agents, bactericidal agents, bacteriostatic agents, agents stimulating the synthesis of dermal or epidermal macromolecules and/or capable of inhibiting or preventing their degradation, collagen synthesis-stimulating agents, elastin synthesis- stimulation agents, agents stimulating the synthesis of lipids and components of the stratum corneum, ceramides, fatty acids, agents that inhibit collagen degradation, matrix metalloproteinase inhibitory agents, agents that inhibit elastin degradation, comedolytic agents , stabilizers, agents for the treatment and/or care of sensitive skin, binding agents, agents regulating sebum production, agents stimulating healing, coadjuvant healing agents, agents stimulating reepithelialization and coadjuvant reepithelialization agents. In one embodiment, the compositions of the invention may comprise a blended aqueous phase and an oil phase. In another embodiment, the compositions of the invention may comprise a blended aqueous phase and an oil phase; wherein the oil phase further comprises not more than 1% by weight of preservatives, more preferably not more than 0.5% by weight. In another embodiment, the compositions of the invention may comprise a blended aqueous phase and an oil phase; wherein the oil phase comprises extracts of at least five different plants wherein at least one, preferably at least two, more preferably at least three plant extracts are selected from the group comprising buchanania lanzan extract, cassia tora extract, pongamia glabra extract, shorea robusta extract. In another embodiment, the compositions of the invention may comprise a blended aqueous phase and an oil phase; wherein the aqueous phase further comprises additional ingredients. The compositions as described herein may be prepared by processes known to the person having ordinary skill in the art of emulsion technology. Typically, the process of preparing emulsion is as follows: a) preparing aqueous phase by mixing water soluble ingredients such as in water, b) preparing oil phase by mixing all oil soluble ingredients, and c) mixing and homogenizing the aqueous and the oil phase. Although applicant does not want to bind themselves to any specific explanation, it is believed that the presence of dispersed aqueous phase in said oil phase to a great extent contributes to the stability of the product, due to the formation of clusters of dispersed and preferably crystallized oil globules. The clusters in turn encapsulate part of the dispersed aqueous phase. In another preferred embodiment, the aqueous phase is prepared by blending water, and other water soluble ingredients. According to a preferred embodiment, the composition of the invention is made from an oil phase that has been prepared by mixing the oil/oils and heating the same at a temperature of about 80-90°C, more preferably 85°C. In another preferred embodiment, the composition of the invention comprises oil extract from about 10% to about 30% by weight, more preferably from about 15% to about 25% by weight. In another preferred embodiment, the aqueous and the oil phase are mixed together at an elevated temperature, preferably at 75-85°C, more preferably at 80°C. Dosage forms for topical administration of the compositions of present invention may include creams, emulsions, dispersions, oils, ointments, balsams, lotions, gels, cream gels or liniments. The compositions of the present invention may be evaluated for different physical, chemical and organoleptic properties including appearance, texture, color, oil globule size, pH, loss on drying, saponification value, chloroform extractives, saponification value, total fatty matter, microbial count and viscosity. Oil globule size: The increase or decrease in the globule sizes indicates the process of instability (Florence and Whitehill, 1982). The multiple droplets may coalesce with the other oil drops, or the internal aqueous droplets may be expelled out individually; or more than one drop may be expelled; or the internal globules may coalesce before being expelled out resulting in the shrinkage of internal droplets; or water may pass from the external phase to the internal aqueous phase resulting in the swelling of internal droplets and then complete rupture of droplets. The globule sizes can be determined by light microscope (Groves, 1 84), (Omotosho et al., 1986) or by electron microscope (Davis et al., 1978), (Adeyeye and Price, 1991). Light scattering and diffraction methods are also used for the determination of globule sizes. The compositions of the invention have oil globule size from about 35 to about lOOmicrons, more preferably from 40 to about 80microns. Viscosity: Viscosity of compositions of the invention was determined using Brookfield Viscometer model. The corresponding reading on the viscometer was noted. The compositions of the invention have a viscosity greater than from about 150000 to about 200000 cps as measured by Brookfield viscometer DVII with helipath. pH: pH value of freshly prepared emulsions and emulsions kept at different conditions were determined by a digital pH-Meter. pH values of compositions of the invention kept at different storage conditions up to 4 weeks have been determined. In one general embodiment the compositions of the present invention fall within the pH range 7.4 to 8.1, more preferably 7.4 to 7.8. Microscopic Tests: Multiple emulsions were analyzed under microscope to confirm the multiple characters. A drop of emulsion was placed on the glass slide and diluted with water and covered by glass cover. A drop of immersion oil was placed on the cover slide and observed under the microscope. Stability tests were performed at different storage conditions for the present compositions to see the effect of these conditions on the storage of the compositions. These tests were performed on samples kept at 37°C ± 0.1 °C, 45°C ± 0.1 °C, 40°C ± 0.1 °C with 75% relative humidity (RH), room temperature (RT; about 25°C). In one general aspect, the compositions of present invention exhibit excellent physical stability characteristics i.e., the compositions show no separation when stored at room temperature (RT) for at least 24 months, more preferably for at least 36 months. The compositions of the present invention have been evaluated clinically using a clinical grading and self-assessment study during a 4-week treatment period with twice daily application. Changes in the skin as a result of the use of the compositions may be measured using any number of techniques known in the art. In certain embodiments, improvements are based on visual appearance by a dermatologist or by self-assessment by the user. In certain embodiments, one or more skin characteristics may be assessed. Such characteristics as tactile roughness, dryness, cracks on the foot heels and pain in the heels may be measured. In certain embodiments, the Physician Preference based on digital images of skin treated with the inventive composition is used to assess the effect of the inventive compositions. In certain embodiments, silicon replicas of the skin may be used to assess the inventive compositions. In certain embodiments, a patient's assessment of their own skin may be used. In one embodiment of the invention the compositions of the invention may be used to treat ailments including dry, chapped, cracked or irritated skin, skin lesions and itch, pain and other such symptoms associated with such ailments. The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. Example 1: Part A: Oil extract composition: Table 1

*to be evaporated.

a) buchanania lanzan seeds, papavar somniferum seeds, cassia tora seeds and pongamia glabra seeds were weighed and crushed, b) curcuma longa rhizome powder was added and mixed, c) the mixture was soaked in about lOOltr. purified water heated to 70-80°C for about 2 hours while maintaining the temperature, d) the mixture was extracted at 95-105°C while refluxing for about 4 hours, e) the water extract was filtered and weighed, f methyl paraben and propyl paraben were added to the water extract and mixed, g) shorea robusta oleoresin and Helianthus annuus oil were added, h) water was evaporated and the resulting oil extract was filtered, and i) butylated hydroxyl anisole was added and dissolved in the oil extract.

Part B: Cream composition: Table 2

Process: a) all the ingredients were weighed accurately, b) water was boiled to about 90°C, c) in part quantity of water, propyl paraben and methyl paraben were added, d) polysorbate 80 and triethanolamine were added with continuous stirring while temperature was maintained at about 85°C, forming the aqueous phase, e) zinc oxide, butylated hydroxyl anisole, butylated hydroxyl toluene, isopropyl myristate, glyceryl monostearate, sorbitan mono stearate, cetosteryl alcohol, sodium lauryl sulfate, stearic acid and kokum butter were mixed with the oil extract while stirring, forming the oil phase, f the oil phase was added to the aqueous phase at 80°C and mixed for about 30 minutes, g) the mixture was cooled to below 45°C and methylisothiazolinone was added and stirred for 20-30 minutes, and h) the remaining quantity of boiled and cooled water was added to the mixture and homogenized to obtain the cream composition.

The composition thus obtained was evaluated for various physical/chemical properties under different stability conditions over a given period as depicted in table 3:

Table3 value (NLT 70%) 5. Chloroform 46.16 44.76 45.25 46.01 45.15 extractive (35- 47%) 6. Total Fatty 40.90 42.19 41.85 43 42.88 Matter (35- 44% w/w)

7. TBC count* 28 12 2 1 24 10 (NMT 250 cfu/gm) 8. TFC count* Nil Nil Nil Nil Nil (NMT 50) 9. Pathogens Absent Absent Absent Absent Absent 10 Viscosity (cps) 1,75000 1,78181 1,82750 1,83001 1,83001 (helipath, rp 12) nota:

The composition was also found to be stable at six month stability testing at 40°C at 75% relative humidity conditions.

Clinical study evaluation: A study was conducted to evaluate the effectiveness of foot care composition on rough, dry cracked feet using a clinical grading and self-assessment system during a 4-week treatment period with twice daily application.

RESULTS:

1. FOOT CRACKS: There was significant improvement in reduction of cracks from baseline to week-1 and onwards. VISUAL ASSESSMENT: (BY DERMATOLOGIST) At baseline visit 84% of subjects had moderate to severe cracks and 16% of subjects had mild cracks on feet. By week-1, 65% subjects had improvement in severe cracks & none of the subjects were in category of severe cracks from week 2 itself. By week-3 the severity further decreased to mild or none cracks and only 2% of subjects remained in moderate category. By week-4, 73% subject had complete resolution of cracks and only 27% of subjects remained with mild cracks. SELF ASSESSMENT: (BY CLIENTS) 89% of subjects felt moderate to excellent feeling in reduction of cracks by week-2. By week-3 all the subjects had good to excellent feeling in reduction of feet cracks and this remained till the end.

2. PAIN: There was significant improvement in reduction of pain from baseline to week-1 and onwards. By week-1, almost all the subjects (89%) had reduction in pain and the same effect was continued to week-2 and onwards. VISUAL ASSESSMENT: (BY DERMATOLOGIST) At baseline visit 9% of subjects had moderate pain and 50% of subjects had mild pain on feet. By week-3, all the subjects showed complete resolution to pain. SELF ASSESSMENT: (BY CLIENTS) Number of subjects with excellent feeling increased week by week and by week-2, almost all the subjects experienced disappearance of pain. By week-2, 96% subjects felt excellent improvement in reduction of pain. All the subjects (100%) had improvement in pain by week-3.

3. DRYNESS / SOFT & SUPPLENESS: There was significant improvement in reduction of dryness from baseline to week-1 and onwards. VISUAL ASSESSMENT: (BY DERMATOLOGIST) At baseline visit, 62% of subjects had moderate to severe dryness and 39% of subjects had mild dryness on feet. By week-1, 84% subjects had improvement in severe dryness. By week-3 almost all the subjects (93%) had no dryness on feet. All the subjects (100%) had improvement in severe dryness from week-2 onwards. SELF ASSESSMENT: (BY CLIENTS) 14% of subjects felt soft and suppleness after 24 hours of application (within 1 day). 59% of subjects felt that their feet became soft and supple after 48 hours (within 2 days) of application and frequency increased to 70% after 72 hours of application (within 3 days) and thereafter 100% by week 1.

4. FEELING OF PLEASANT ODOR IN FEET: All the subjects felt pleasant odor in feet from week 1 onwards on the usage of Foot Care Cream. Based on the fact that the cream is very effective in treating foot cracks, dryness and pain, it can also be said that the remedy will be effective in healing other dry skin conditions such as chapped hands, chilblains etc. While a number of presently preferred and various alternative embodiments of the present invention have been described in detail above, various other adaptations and modifications of the cream formulation for topical application to an external portion of a human body may be made by those persons who are skilled in the relevant art without departing from either the spirit of the invention or the scope of the appended claims. We Claim;

1. A topical composition comprising about 10 to about 30% oil extract wherein the oil extract comprises extracts of at least five different plants wherein at least one plant extract is selected from the group comprising buchanania lanzan extract, cassia tora extract, pongamia glabra extract, shorea robusta extract.

2. The topical composition as claimed in claim 1, wherein the at least five different plants are selected from the group comprising buchanania lanzan, cassia tora, pongamia glabra, shorea robusta. papavar somniferam, curcuma longa and helianthus annus.

3. The topical composition as claimed in claim 1, wherein the oil extract comprises not more than 0.5% by weight of preservatives.

4. The topical composition as claimed in claim 1, wherein the composition is in the form of creams, emulsions, dispersions, oils, ointments, balsams, foams, lotions, gels, cream gels or liniments.

5. The topical composition as claimed in claim 1, wherein the composition is in the form of cream.

6. The topical composition as claimed in claim 1, wherein the composition further comprises one or more cosmetically or pharmaceutically acceptable ingredients comprising preservatives/antioxidants/chelating agents, vitamins, dyes/coloring agents, proteins/amino acids, plant extracts, humectants/conditioners/moisturizers,fragrances/perfumes, oils/emollients/lubricants, penetrants, thickeners/viscosity modifiers, surfactants/ detergents/ emulsifiers/opacifying agents, liquid vehicles/solvents and pH adjusting agents/buffers/neutralizing agents.

7. The topical composition as claimed in claim 1, wherein the composition further comprises one or more cosmetically or pharmaceutically active ingredients comprising antiseptic agents, antiperspirant agents, anti-inflammatory agents and/or analgesics, anti- itching agents, calming agents, anesthetic agents, skin relaxant agents, free radical scavengers and/or agents against atmospheric pollution, reactive carbonyl species scavengers, antimicrobial agents, antifungal agents, fungistatic agents, bactericidal agents, bacteriostatic agents, agents stimulating the synthesis of dermal or epidermal macromolecules and/or capable of inhibiting or preventing their degradation, collagen synthesis-stimulating agents, elastin synthesis-stimulation agents, agents stimulating the synthesis of lipids and components of the stratum corneum, ceramides, fatty acids, agents that inhibit collagen degradation, matrix metalloproteinase inhibitory agents, agents that inhibit elastin degradation, comedolytic agents, , stabilizers, agents for the treatment and/or care of sensitive skin, binding agents, agents regulating sebum production, agents stimulating healing, coadjuvant healing agents, agents stimulating reepithelialization, cpadjuvant reepithelialization agents.

8. The topical composition as claimed in claim 1, wherein the oil extract is prepared by a process comprising the steps: a) weighing, drying and powdering the plants, b) extracting the powder with a solvent by soaking for about 2 hours at a temperature between 70°-80°C followed by extracting at a temperature between 98°-105°C at reflux for about 4 hours, c) filtering the extract and adding one or more preservatives, d) adding one or more cosmetically or pharmaceutically acceptable ingredients, e) evaporating the water at 98-100°C to obtain hot oil extract, f) adding one or more antioxidants to the extract, and g) cooling the oil extract obtained.

The topical composition as claimed in claim 1, wherein the composition is prepared by a process comprising the steps: a) heating water to about 80- 00°C, b) adding one or more cosmetically or pharmaceutically acceptable ingredients to form the aqueous phase and mixing while maintaining the temperature at 85°C, c) mixing oil extract with one or more cosmetically or pharmaceutically acceptable ingredients, d) adding oil phase into aqueous phase at about 80°C and mixing, and cooling the mixture to below 45°C and further adding one or more ingredients including perfumes to the mixture to obtain final composition. International application No PCT/IN2016/0OQ012

A. CLASSIFICATION O F SUBJECT MATTER INV. A61K8/97 A61Q19/O0 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols A61K A61Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal , WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

" Pandeya Udvartana" , 1 ,3-9 TKDL, , 1 January 1990 (1990-01-01) , XP003027823 , the whole document 2

SHARMA JYOTSANA ET AL: " Ethnomedi cinal 1-9 p l ants used t o treat skin di seases by Tharu communi t y of d i stri ct Udham Singh Nagar, Uttarakhand, India" , JOURNAL OF ETHN0PHARMAC0L0GY, vol . 158, 2014, pages 140-206, XP029099058, ISSN : 0378-8741, D0I : 10. 1016/J .JEP.2014. 10.004 page 5 pages 8 , 17 page 10

/ -

X Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand "A" document defining the general state of the art which is not considered the principle or theory underlying the invention to be of particular relevance "E" earlier application or patent but published on or after the International "X" document of particular relevance; the claimed invention cannot be filing date considered novel or cannot be considered to involve an inventive "L" document which may throw doubts on priority claim(s) orwhich is step when the document is taken alone cited to establish the publication date of another citation or other " document of particular relevance; the claimed invention cannot be special reason (as specified) considered to involve an inventive step when the document is "O" document referring to a n oral disclosure, use, exhibition or other combined with one or more other such documents, such combination means being obvious to a person skilled in the art "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family

Date of the actual completion of the international search Date of mailing of the international search report

9 June 2016 17/06/2016

Name and mailing address of the ISA/ Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 Simon, Frederi c International application No PCT/IN2016/0OQ012

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X Mahtab Zaki r a Siddiqui ET AL: "Buchanani a 1,3-9 Lanzan: a species of enormous potenti al s " , World Journal of Pharmaceuti cal Sciences , 1 Apri l 2014 (2014-04-01) , pages 374-379 , XP055278781, Retri eved from the Internet: URL: http : //www. j psonl i ne . org/admi n/upl oad s/FKJbny.pdf [retri eved on 2016-06-08] Y page 375 , left-hand col umn 2 page 376, right-hand col umn

X HARISHCHANDRAS PRAKASH ET AL: "Curati ve 1,3-9 properties of Buchanania l anzan: As eval uated by i t s anti -oxi dant, anti - i nfl ammatory and DNA protecti ve properties" , JOURNAL OF NATURAL PHARMACEUTICALS, vol . 3 , no. 2 , 1 January 2012 (2012-01-01) , page 7 1 , XP055278869, ISSN : 2229-5119, D0I : 10.4103/2229-5119 . 102748 Y abstract 2 page 75

X GB 2 441 599 A (SHAH ELADEVI MAHENDRA 1-9 [GB] ) 12 March 2008 (2008-03-12) exampl e 5 page 16 - page 19

X A. VI JAYALAKSHMI ET AL: "Anti -psoriati c 1,3-9 activi t y of f l avonoids from Cassi a tora l eaves usi ng the rat ul traviol et B ray photodermati t i s model " , REVISTA BRASI LEI RA DE FARMAC0GN0SIA- BRAZI LIAN JOURNAL OF PHARMACOGNOSY, vol . 24, no. 3 , 1 May 2014 (2014-05-01) , pages 322-329 , XP055278928, B R ISSN : 0102-695X, D0I : 10. 1O16/j .bjp.2O14.O7 .010 Y abstract 2 page 327 , right-hand col umn page 328, left-hand col umn

-/-- International application No PCT/IN2016/0OQ012

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X M. S. AHSHAWAT ET AL: "Preparati on and 1,3-9 characteri zati on of herbal creams for improvement of ski n v i scoelasti c properties" , INTERNATIONAL JOURNAL OF COSMETIC SCI ENCE. , vol . 30, no. 3 , 25 March 2007 (2007-03-25) , pages 183-193, XP055278940, NL ISSN : 0142-5463, D0I : 10. 1111/j . 1468-2494. 2008. 00442.x Y table 1 2

X Savi t a Sangwan ET AL: "A Revi ew on 1,3-9 Pongamia Pinnata (L. ) Pierre: A Great Versati l e Leguminous Plant" , Nature and Sci ence Nature and Sci ence, 1 January 2010 (2010-01-01) , XP055278965 , Retri eved from the Internet: URL:http://www. sci encepub.net/nature/ns081 1/I9_3880ns0811_130_139.pdf Y page 130 2 table 4

X US 2011/097424 Al (REDDY N B BAKTHA [IN] 1,3-9 ET AL) 28 Apri l 2011 (2011-04-28) Y paragraphs [0004] , [0005] , [0017] , 2 [0049] - [0053]

X DE 101 40 538 Al (BEI ERSD0RF AG [DE] ) 1,3-9 6 March 2003 (2003-03-06) Y paragraphs [0007] , [0017] 2

X AL MUQARRABUN L M R ET AL: "Medi cinal 1,3-9 uses , phytochemi stry and pharmacol ogy ofPongami a pi nnata(L. ) Pi erre: A revi ew" , JOURNAL OF ETHN0PHARMAC0L0GY, vol . 150, no. 2 , 2013 , pages 395-420, XP028765931, ISSN : 0378-8741, D0I : 10. 1016/J .JEP.2013.08.041 Y page 396 2 table 1

X US 4 534 981 A (ZAB0TT0 ARLETTE [FR] ET 1,3-9 AL) 13 August 1985 (1985-08-13) Y col umn 2 , l ine 6 - l i ne 12 2

X GB 2 326 595 A (COUNCI L SCI ENT IND RES 1,3-9 [IN] ) 30 December 1998 (1998-12-30) Y page 1, i ne 1 - ine 9 2

-/-- International application No PCT/IN2016/0OQ012

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

HEMANTA MUKHERJEE ET AL: "Eval uation Of 1 ,3-9 the wound heal ing acti v i t y of Shorea robusta, an Indian ethnomedi c i ne, and i t s i solated consti tuent(s) i n topi cal formul ati on" , JOURNAL OF ETHNOPHARMACOLOGY, vol . 149 , no. 1 , 1 August 2013 (2013-08-01) , pages 335-343 , XP055277401, I E ISSN : 0378-8741, D0I : 10. 1016/j .jep.2013.06.045 abstract 2

HEMA SHARMA DATTA ET AL: "Wound Heal i ng 1 , 3 - 9 Activi t y of Topi cal Appl i cati on Forms Based on " , EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM, vol . 87, no. 2 , 1 January 2011 (2011-01-01) , pages 159-10, XP055279397, Uni ted States ISSN : 1741-427X, D0I : 10.2174/1568011043352704 page 9 - page 10

PETER FARLEY : "Shoul d topi cal opi oid analgesi c s be regarded a s effecti ve and safe when appl ied t o chroni c cutaneous 1esi ons? " JOU RNAL ' OF PHARMACY AND PHARMACO LOGY , vol . 63 , no. 6 , 3 May 20 1 1 (201 1 -05 -03 ) , pages 747 - 756 , XP055279022 , LONDON; GB ISSN : 0022 -3573 , D0 I : 10 . 1 1 11/ j . 2042 - 7 158 . 201 1 . 01252 . x abstract pages 747 , 749

VELAYUDHAN ET AL: "Ethnobotany of turmeri c (Curcuma longa L. ) " , INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE, NATIONAL INSTITUTE OF SCI ENCE COMMUNICATION AND INFORMATION RESOURCES, NEW DELHI - INDIA, vol . 11, no. 4 , 1 October 2012 (2012-10-01) , pages 607-614, XP018029638, table 1

/ - C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

Gul zar Al am ET AL: "WOUND HEALING POTENTIAL OF SOME MEDICINAL PLANTS" , Internati onal Journal of Pharmaceuti cal Sci ences Revi ew and Research Page, 1 January 2011 (2011-01-01) , XP055279419 , Retri eved from the Internet: URL: http://gl obal researchonl i ne.net/journa 1content s/vol ume9i ssuel/Arti c l e-026 . pdf [retri eved on 2016-06-09] pages 141 , 142

ANONYMOUS: "Cracked Heel s : stop them i n 1-9 thei r tracks" , BEST PRACTICES JOURNAL, no. 65 , 1 December 2014 (2014-12-01) , pages 39-40, XP055279035 , ISSN : 1177-5645

GABRI ELLE 0 ' SULLIVAN ET AL: "What 1-9 treatments rel i eve pai nful heel cracks? " , THE JOURNAL OF FAMI LY PRACTICE, vol . 61 , no. 10, 1 October 2012 (2012-10-01) , pages 662-663 , XP055279060, the whol e document Patent document Publication Patent family Publication cited in search report date member(s) date

GB 2441599 A 12-03-2008 NONE

US 2011097424 Al 28-04-2011 NONE

DE 10140538 Al 06-03-2003 NONE

US 4534981 A 13-08-1985 A R 229442 Al 15-08-1983 AT 378911 B 25-10-1985 AU 558377 B2 29-01-1987 AU 9060682 A 26-05-1983 BE 895016 Al 16-05-1983 CA 1174172 A 11-09-1984 CH 652592 A5 29-11-1985 DE 3242385 Al 26-05-1983 ES 8400868 Al 16-02-1984 FR 2516380 Al 20-05-1983 GB 2109233 A 02-06-1983 I T 1156339 B 04-02-1987 P H0244445 B2 04-10-1990 P S5892606 A 02-06-1983 LU 83765 Al 01-09-1983 MX 160196 A 21-12-1989 NL 8204444 A 16-06-1983 US 4534981 A 13-08-1985

GB 2326595 A 30-12-1998 GB 2326595 A 30-12-1998 US 6126950 A 03-10-2000